Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Hologic is a medical technology company specializing in women's health diagnostics and imaging, with dominant market positions in mammography systems (3D Genius tomosynthesis), molecular diagnostics (Panther platform for STI/HPV testing), and surgical products (MyoSure tissue removal). The company generates ~$4.1B in revenue across four divisions, with competitive moats built on installed base economics, FDA-approved proprietary technologies, and recurring consumable revenue streams.
Hologic operates a razor-razorblades model: capital equipment sales (mammography systems, Panther instruments) create installed bases that generate high-margin recurring revenue from consumables (assay kits, reagents), service contracts, and software upgrades. The Panther platform processes 1,000+ tests daily at reference labs, generating $200-400 per instrument annually in consumables. Breast Health benefits from mandated annual screening guidelines and multi-year service agreements. Gross margins of 61% reflect pricing power from proprietary FDA-cleared technologies and switching costs embedded in lab workflows.
Diagnostic testing volumes: STI/HPV assay growth, COVID/respiratory testing demand fluctuations
Breast Health capital equipment placements: 3D mammography system installations in US hospitals and international markets
Surgical procedure volumes: MyoSure and NovaSure utilization tied to elective gynecological procedures
Gross margin trajectory: mix shift between high-margin diagnostics consumables vs. lower-margin capital equipment
FDA approvals and product launches: new assay menu expansions on Panther platform, next-gen imaging systems
Reimbursement pressure: CMS and private payer rate cuts for diagnostic tests (HPV, STI panels) could compress margins despite volume growth
Technological disruption: liquid biopsy competitors (Exact Sciences, Guardant) could displace traditional cytology and tissue-based diagnostics
Regulatory risk: FDA scrutiny on diagnostic accuracy, particularly for molecular assays, could delay new product approvals or require costly post-market studies
Breast imaging competition: GE Healthcare, Siemens Healthineers, and Fujifilm competing on AI-enhanced mammography and lower-cost digital systems
Molecular diagnostics fragmentation: Roche, Abbott, Qiagen, and Cepheid competing for lab placements with broader menu offerings beyond women's health
Surgical device competition: Medtronic, Boston Scientific offering alternative minimally invasive gynecological solutions
Modest leverage at 0.48x debt/equity is manageable, but $3.2B in long-term debt requires $150-200M annual interest expense, consuming ~15% of operating cash flow
Acquisition integration risk: historical M&A (Cytyc, Gen-Probe, Interlace) drove growth, but future deals require successful integration to avoid goodwill impairments
low-to-moderate - Diagnostic testing is non-discretionary and driven by disease prevalence and screening guidelines rather than GDP. Breast Health benefits from mandated annual mammograms (80%+ compliance in US). However, capital equipment purchases by hospitals are moderately cyclical, sensitive to hospital budgets and elective procedure volumes. Surgical division shows higher cyclicality as MyoSure/NovaSure procedures can be deferred during economic stress.
Rising rates have modest negative impact through two channels: (1) hospital capital budgets tighten as financing costs increase, potentially delaying mammography system purchases, and (2) valuation multiple compression for med-tech stocks as discount rates rise. However, Hologic's 0.48x debt/equity and $1.1B operating cash flow provide insulation from direct financing cost pressures. Demand for diagnostic testing remains largely rate-insensitive.
Minimal direct credit exposure. Revenue is primarily from hospitals, reference labs, and government-reimbursed procedures with stable payment profiles. No meaningful consumer credit risk. Hospital financial health can indirectly affect capital equipment purchasing, but service contracts and consumables provide revenue stability.
value-to-growth hybrid - Attracts investors seeking stable med-tech cash flows (5.5% FCF yield) with modest growth (low-single-digit organic revenue growth). The 61% gross margin and recurring revenue model appeal to quality-focused funds. Post-COVID normalization has compressed multiples (16.9x EV/EBITDA), attracting value investors betting on diagnostic volume recovery. Limited dividend (company prioritizes buybacks) reduces income investor appeal.
moderate - Healthcare beta typically 0.7-0.9, with lower volatility than broader market. Stock moves on earnings surprises tied to diagnostic volumes and capital equipment cycles. COVID created abnormal volatility (2020-2022 revenue swings), but base business shows predictable quarterly patterns. Institutional ownership ~90% dampens retail-driven volatility.
